InterPAD - DETAILS

3-GlcGlc-20-GlcGlc-ginsenoside, arasaponin E1, ginsenoside Rb1, ginsenoside-Rb1, gynosaponin C, gypenoside III, notoginsenoside Rb1, panax saponin E, panaxoside Rb1, pseudoginsenoside D, sanchinoside E1, sanchinoside Rb1

No.	Title	Href
1	Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells. Dis Markers. 2022 Jan 13;2022:3833489. doi: 10.1155/2022/3833489.	`Click`
2	Ginsenoside Rb1 for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1. Phytomedicine. 2023 Jul;115:154776. doi: 10.1016/j.phymed.2023.154776.	`Click`

No.

Title

Href

Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells. Dis Markers. 2022 Jan 13;2022:3833489. doi: 10.1155/2022/3833489.

Click

Ginsenoside Rb1 for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1. Phytomedicine. 2023 Jul;115:154776. doi: 10.1016/j.phymed.2023.154776.

Click

Name	Ginsenoside Rb1
PubChem CID	9898279
Molecular Weight	1109.3g/mol
Synonyms	3-GlcGlc-20-GlcGlc-ginsenoside, arasaponin E1, ginsenoside Rb1, ginsenoside-Rb1, gynosaponin C, gypenoside III, notoginsenoside Rb1, panax saponin E, panaxoside Rb1, pseudoginsenoside D, sanchinoside E1, sanchinoside Rb1
Formula	C₅₄H₉₂O₂₃
SMILES	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(C(O8)CO)O)O)O)O)O)O)C
InChI	1S/C54H92O23/c1-23(2)10-9-14-54(8,77-48-44(69)40(65)37(62)29(74-48)22-70-46-42(67)38(63)34(59)26(19-55)71-46)24-11-16-53(7)33(24)25(58)18-31-51(5)15-13-32(50(3,4)30(51)12-17-52(31,53)6)75-49-45(41(66)36(61)28(21-57)73-49)76-47-43(68)39(64)35(60)27(20-56)72-47/h10,24-49,55-69H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28+,29+,30-,31+,32-,33-,34+,35+,36+,37+,38-,39-,40-,41-,42+,43+,44+,45+,46+,47-,48-,49-,51-,52+,53+,54-/m0/s1
InChIKey	GZYPWOGIYAIIPV-JBDTYSNRSA-N
CAS Number	41753-43-9
ChEMBL ID	CHEMBL501515
ChEBI ID	CHEBI:67989
Drug Bank ID	DB06749
KEGG ID	C20713
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Chineses Pinyin	RenShen
Use Part	Root
Habitat	JiLin, LiaoNing, HeiLongJiang
Flavor	Sweet, Mildly bitter
Meridian Tropism	Spleen, Lung, Heart, Kidney
Species	>Kingdom: Viridiplantae 　-->Phylum: Streptophyta 　　-->Class: Equisetopsida 　　　-->Order: Apiales 　　　　-->Family: Araliaceae 　　　　　-->Genus: Panax 　　　　　　-->Species: Panax ginseng

Pair Name	Ginsenoside Rb1, Apatinib
Partner Name	Apatinib
Disease Info	[ICD-11: 2B6E]	Hypopharyngeal carcinoma		Investigative
Biological Phenomena	Induction-->Immunomodulatory
Gene Regulation	Up-regulation	Expression	CD4	hsa920
	Down-regulation	Expression	CD8A	hsa925
	Down-regulation	Expression	HK2	hsa3099
	Down-regulation	Expression	KDR	hsa3791
	Down-regulation	Expression	PECAM1	hsa5175
	Down-regulation	Expression	SLC2A4	hsa6517
	Down-regulation	Expression	SOX5	hsa6660
In Vitro Model	FaDu	Hypopharyngeal squamous cell carcinoma	Homo sapiens (Human)	CVCL_1218
In Vitro Model	Rca-B	Squamous cell carcinoma	Rattus norvegicus (Rat)	CVCL_5U48
Result	A combination of apatinib and G-Rb1 induced more tumor cell apoptosis and reduced cell proliferation than the individual drug treatment and promote antitumor immunity by enhancing immunomodulatory molecules. Thus, we believe that this study could serve as a valuable platform to assess the synergetic anticancer effects of the herbal as well as synthetic medicines.

Pair Name	Ginsenoside Rb1, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Inhibition-->Two efflux pumps
Gene Regulation	Down-regulation	Expression	ABCB1	hsa5243
	Down-regulation	Expression	GLI2	hsa2736
	Down-regulation	Expression	PTCH1	hsa5727
	Down-regulation	Expression	SHH	hsa6469
In Vitro Model	A549/DDP	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_C0W4
In Vivo Model	6×10⁶ A549 or A549/DDP cells were subcutaneously injected into BALB/c-nu mice to establish the model of tumor-bearing mice.
Result	Ginsenoside Rb1 for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1